{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T03:56:03Z","timestamp":1790222163717,"version":"4.1.0"},"reference-count":48,"publisher":"The Journal of Rheumatology","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>To assess clinical outcomes including imaging findings on computed tomography (CT), pulmonary function testing (PFT), and glucocorticoid (GC) use in patients with the antisynthetase syndrome (AS) and interstitial lung disease (ILD) treated with rituximab (RTX).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We retrospectively identified all patients at 2 institutions with AS-ILD who were treated with RTX. Baseline demographics, PFT, and chest CT were assessed before and after RTX. Two radiologists independently evaluated CT using a standardized scoring system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Twenty-five subjects at the Brigham and Women\u2019s Hospital (n = 13) and University of Pittsburgh Medical Center (n = 12) were included. Antisynthetase antibodies were identified in all patients (16 Jo1, 6 PL-12, 3 PL-7). In 21 cases (84%), the principal indication for RTX use was recurrent or progressive ILD, owing to failure of other agents. Comparing pre- and post-RTX pulmonary variables at 12 months, CT score and forced vital capacity were stable or improved in 88% and 79% of subjects, respectively. Total lung capacity (%) increased from 56 \u00b1 13 to 64 \u00b1 13 and GC dose decreased from 18 \u00b1 9 to 12 \u00b1 12 mg\/day. Although DLCO (%) declined slightly at 1 year, it increased from 42 \u00b1 17 to 70 \u00b1 20 at 3 years. The most common imaging patterns on CT were nonspecific interstitial pneumonia (NSIP; n = 13) and usual interstitial pneumonia\/fibrotic NSIP (n = 5), of which 5 had concurrent elements of cryptogenic organizing pneumonia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Stability or improvement in pulmonary function or severity of ILD on CT was seen in most patients. Use of RTX was well tolerated in the majority of patients. RTX may play a therapeutic role in patients with AS-ILD, and further clinical investigation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.170541","type":"journal-article","created":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T07:35:11Z","timestamp":1522568111000},"page":"841-850","source":"Crossref","is-referenced-by-count":92,"title":["Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review"],"prefix":"10.3899","volume":"45","author":[{"given":"Tracy J.","family":"Doyle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata","family":"Dhillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Madan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Cabral","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine A.","family":"Fletcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane C.","family":"Koontz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C.","family":"Osorio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan O.","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V.","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F.","family":"Dellaripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"2018112909384165000_45.6.841.1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0176-8"},{"key":"2018112909384165000_45.6.841.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706"},{"key":"2018112909384165000_45.6.841.3","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0180"},{"key":"2018112909384165000_45.6.841.4","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000104"},{"key":"2018112909384165000_45.6.841.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.30513"},{"key":"2018112909384165000_45.6.841.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2014.11.026"},{"key":"2018112909384165000_45.6.841.7","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201800"},{"key":"2018112909384165000_45.6.841.8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21895"},{"key":"2018112909384165000_45.6.841.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-014-9665-7"},{"key":"2018112909384165000_45.6.841.10","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0172-z"},{"key":"2018112909384165000_45.6.841.11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2009.02207.x"},{"key":"2018112909384165000_45.6.841.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.21617"},{"key":"2018112909384165000_45.6.841.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"2018112909384165000_45.6.841.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.21778"},{"key":"2018112909384165000_45.6.841.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.22025"},{"key":"2018112909384165000_45.6.841.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909905"},{"key":"2018112909384165000_45.6.841.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-1-200701020-00006"},{"key":"2018112909384165000_45.6.841.18","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.029694"},{"key":"2018112909384165000_45.6.841.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.37754"},{"key":"2018112909384165000_45.6.841.20","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-013-8408-9"},{"key":"2018112909384165000_45.6.841.21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu024"},{"key":"2018112909384165000_45.6.841.22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew146"},{"key":"2018112909384165000_45.6.841.23","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1002\/art.38270","article-title":"Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis","volume":"66","author":"Aggarwal","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2018112909384165000_45.6.841.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker088"},{"key":"2018112909384165000_45.6.841.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204522"},{"key":"2018112909384165000_45.6.841.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2009.09.003"},{"key":"2018112909384165000_45.6.841.27","doi-asserted-by":"publisher","DOI":"10.1111\/resp.12214"},{"key":"2018112909384165000_45.6.841.28","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep157"},{"key":"2018112909384165000_45.6.841.29","doi-asserted-by":"crossref","first-page":"e639","DOI":"10.1097\/MJT.0000000000000245","article-title":"Successful treatment of life-threatening interstitial lung disease secondary to antisynthetase syndrome using rituximab: A case report and review of the literature","volume":"23","author":"Dasa","year":"2016","journal-title":"Am J Ther"},{"key":"2018112909384165000_45.6.841.30","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150844"},{"key":"2018112909384165000_45.6.841.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133702"},{"key":"2018112909384165000_45.6.841.32","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-0859-x"},{"key":"2018112909384165000_45.6.841.33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev004"},{"issue":"Suppl 100","key":"2018112909384165000_45.6.841.34","first-page":"181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909384165000_45.6.841.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.01.001"},{"key":"2018112909384165000_45.6.841.36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew195"},{"key":"2018112909384165000_45.6.841.37","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.54.2748"},{"key":"2018112909384165000_45.6.841.38","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.159.1.9712108"},{"key":"2018112909384165000_45.6.841.39","first-page":"419","article-title":"Lung volumes in healthy nonsmoking adults","volume":"18","author":"Crapo","year":"1982","journal-title":"Bull Eur Physiopathol Respir"},{"key":"2018112909384165000_45.6.841.40","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1183\/09041950.041s1693","article-title":"Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society","volume":"16","author":"Cotes","year":"1993","journal-title":"Eur Respir J Suppl"},{"key":"2018112909384165000_45.6.841.41","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2211-6"},{"key":"2018112909384165000_45.6.841.42","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2106157"},{"key":"2018112909384165000_45.6.841.43","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200211-1311OC"},{"key":"2018112909384165000_45.6.841.44","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-1474"},{"key":"2018112909384165000_45.6.841.45","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12016-009-8123-4","article-title":"Interpretation of pulmonary function test: Issues and controversies","volume":"37","author":"Berry","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"key":"2018112909384165000_45.6.841.46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-068999"},{"key":"2018112909384165000_45.6.841.47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-01-0233"},{"key":"2018112909384165000_45.6.841.48","doi-asserted-by":"publisher","DOI":"10.1002\/art.22810"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.170541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:31:45Z","timestamp":1543501905000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.170541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":48,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6,1]]},"published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.3899\/jrheum.170541"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.170541","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,1]]}}}